138th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2170401296151939 Karnataka164924842322998 Delhi1441271293624098 Uttar Pradesh118038698332028 West Bengal89666630601954 Telangana7751354330615 Bihar7578648673419 Gujarat68855517922604 Assam5549737225132 Rajasthan5065636310776 Odisha4419328698307 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3312020862107 Jammu and Kashmir2439020862459 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Tripura6014408437 Puducherry5123291475 Manipur3635192711 Himachal Pradesh3242201513 Nagaland26888937 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
Business Companies 24 Jun 2020 Cipla to price remde ...

Cipla to price remdesivir version for COVID-19 under Rs 5,000

REUTERS
Published Jun 24, 2020, 8:47 am IST
Updated Jun 24, 2020, 3:58 pm IST
Gilead said on Monday it is targeting remdesivir supply for more than 2 million COVID-19 patients by the end of the year.
Cipla Ltd will price its generic version of Gilead Sciences Inc’s antiviral drug remdesivir for use in COVID-19 patients. (Photo- Twitter)
 Cipla Ltd will price its generic version of Gilead Sciences Inc’s antiviral drug remdesivir for use in COVID-19 patients. (Photo- Twitter)

BENGALURU: Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc’s antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.

Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees.

 

Beximco Pharmaceuticals Ltd, one of Bangladesh’s largest drugmakers, in May became the first company in the world to introduce a generic variant of remdesivir.

Reuters exclusively reported that the company was planning to price its version at between 5,000 to 6,000 takas ($59 to $71) per vial.

Remdesivir, intravenously administered in hospitals, is the first treatment to show improvement in COVID-19 trials. It has been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.

 

Cipla, in an e-mailed statement, did not provide details on when the treatment, called Cipremi, will be available.

Remdesivir has yet to be priced in the United States.

Gilead said on Monday it is targeting remdesivir supply for more than 2 million COVID-19 patients by the end of the year.

The expectations suggest sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.

Cases of the novel coronavirus in India stood at 440,215 on Tuesday, health ministry data showed https://www.mohfw.gov.in, while the death toll stood at 14,011. The country is on track to overtake Russia as the third most affected country by cases.

 

...
Location: India, Karnataka, Bengaluru




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT